Accelerating Peptide Therapeutics from Concept to Clinic
Partner with JYMed Peptide’s integrated platforms and 16 years of peptide‐only expertise to fast-track your program—delivering safer, more effective candidates in record time.
Your Trusted Partner in Peptides: From Discovery to Commercialization
With over 15 years of peptide-only expertise, JYMed Peptide supports programs from discovery through commercialization with proven reliability. Backed by 120+ scientists and state-of-the-art platforms including SPPS, LPPS, HPPS, advanced modifications, formulation, and purification, we accelerate timelines, reduce development risks, and scale complex peptides with confidence.
Advanced Peptide Synthesis Platforms
Solid Phase Peptide Synthesis (SPPS)
Our SPPS platform helps you access long and complex peptides with reliable precision. It ensures your projects move forward quickly without compromising quality.
Liquid Phase Peptide Synthesis (LPPS)
LPPS is built for large-scale needs, giving you consistent results from batch to batch. It keeps production cost-effective while meeting regulatory standards.
Peptide-Anchored Liquid-Phase Peptide Synthesis (PA-LPPS)
This technology uses a class of molecules with unique physical and chemical properties as soluble carbon end tags (C-Tags) to replace traditional solid-phase insoluble resins. The liquid-phase peptide synthesis (LPPS) method is then applied to anchor the growing peptide chains, with all reactions carried out in solution.
Minimum Protecting Group Strategy (MP-SPPS)
We simplify synthesis and reduce costs by limiting the use of expensive reagents. This approach minimizes side reactions and supports smoother scale-up.
Hybrid-Phase Peptide Synthesis (HPPS)
HPPS brings together multiple synthesis strategies to unlock new possibilities. It enables the design of highly specialized or customized peptides that are beyond the reach of conventional methods.
Building block/fragment design for complex peptides
Our modular design approach makes even the toughest peptides achievable. It offers flexibility while ensuring accuracy in every sequence.
Peptide Modification Services
At JYMed Peptide, we apply a wide range of modification strategies to enhance peptide stability, potency, and delivery. These capabilities allow us to optimize pharmacokinetics, enable targeted therapies, and expand the applications of peptide drugs.
Labeling Engineering
We incorporate tracer groups such as fluorescent labels, biotin, or radioisotopes into peptides. These modifications enable tracking, detection, and target validation for research and therapeutic development.
Conjugation Technology
Our peptide-drug conjugation services integrate three essential elements: a targeting peptide, a linker, and a drug payload. This architecture enables selective delivery of cytotoxins or therapeutic components with controlled release and high potency.
PEGylation and Lipidation
PEGylation improves peptide pharmacokinetics by extending half-life, enhancing stability, and reducing immunogenicity. This helps your candidates remain active longer in circulation and increases therapeutic efficacy.
Cyclization Modification
We offer diversified cyclization strategies including disulfide bonds, thioether bonds, trisulfide bonds, alkylation, and lactam bridges. These modifications strengthen peptide conformation, enhance receptor binding, and improve resistance to enzymatic degradation.
Peptide Formulation Services
Optimized Formulations for Stability, Delivery & Patient Compliance
Lyophilized Powder Formulations
In modern world where the stability of medications is paramount, the lyophilization process in the pharmaceutical industry serves as a critical safeguard. Lyophilization, commonly known as “freeze-drying”, is not just a method; it’s a necessity that ensures the longevity and efficacy of vital drugs.
JYMed Peptide have a complete facilities for the nuanced stages of freeze drying, which ensure the “Enhanced Stability of peptide’s APIs, Increased Shelf Life, Reduced Transportation and Storage Costs and Protection from Contamination”
Aqueous Solution Formulations
Boost solubility and bioavailability for immediate therapeutic effect.
Sustained-Release Depot Formulations
Prolong drug exposure to improve patient compliance and treatment outcomes.
JY-FIS™ Purification Technology Platform
Separation and Purification Technologies
Our platform combines continuous chromatography and high-performance liquid chromatography systems. These methods deliver fast separation, lower solvent consumption, higher efficiency, and excellent scalability for diverse peptides.
Spray Dry Process Development
Spray drying offers a faster and more efficient alternative to lyophilization. It enables rapid scalability from lab to industrial production levels.
Lyophilization Process Development
We maintain peptide structural integrity and bioactivity through advanced lyophilization. Products are easily reconstituted with water while ensuring long-term stability.
Recrystallization
Recrystallization in LPPS strategies provides high-purity peptides and fragments. It also optimizes crystal structures while offering cost-effective manufacturing benefits.
Partner with JYMed Peptide for Trusted Peptide Innovation
Join forces with JYMed Peptide to unlock the full potential of peptide therapeutics. Our end-to-end CDMO services—spanning synthesis, modification, formulation, and purification—are backed by a global team of 600+ employees including 100+ scientists and state-of-the-art facilities (10 cGMP lines, 30 000 L+ reactor volume). Experience faster timelines, scalable capacity, and GMP-compliant quality.
COMPREHENSIVE PEPTIDE TECHNOLOGY PLATFORMS
Integrated Platforms for Accelerated Peptide Innovation
At JYMed Peptide, we bring every stage of peptide development fully in-house—combining Synthesis, Modification, Formulation, and Purification—backed by a global team of 600+ professionals across three sites, including 100+ scientists.
State-of-the-Art Facilities:
~54,000 sqm total plant area with 10 cGMP peptide API production lines
30,000 L+ SPPS/LPPS reactor volume delivering 4+ tons of peptide APIs annually (expanding to 10+ tons by 2027)
Proven Track Record:
2,900+ CRO projects completed
50+ CDMO programs delivered
Ready to see how our end-to-end platforms can power your next peptide candidate?